Search Results 251-260 of 17359 for hba1c

1. Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States - Mayo Clinic

   Uncontrolled diabetes (HbA1c ≥ 9.0%) within past 24 weeks 17. Kidney function abnormalities including: a. Dialysis b. Baseline epidermal growth factor ...

2. Gene Therapy For Cardiomyopathy Associated With Friedreich's Ataxia - Mayo Clinic

   Uncontrolled diabetes (Hemoglobin A1c [HbA1c] levels > 7%. A history of drug abuse or alcohol abuse within the past year as judged by the investigator. Any ...

3. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Dupilumab In Adult Patients With Bullous Pemphigoid - Mayo Clinic

   Examples include, but are not limited to, patients with short life expectancy, patients with uncontrolled diabetes (HbA1c ≥ 9%), patients with ...

4. A study to test whether survodutide helps people with a liver disease called NASH/MASH who have moderate or advanced liver fibrosis - Mayo Clinic

   HbA1c > 10% (> 86 mmol/mol) as measured by the central laboratory at screening. Impaired renal function, defined as eGFR 2x ULN as measured by the central ...

5. A Study Comparing the Safety and Effectiveness of Lonapegsomatropin with Placebo and Somatropin in Adults with Growth Hormone Deficiency - Mayo Clinic

   Poorly controlled diabetes, defined as HbA1c >7.5% at screening. 2. Diabetes mellitus (defined as HbA1c ≥6.5% and/or fasting plasma glucose ≥126 mg/dL ...

6. A Multi-Center Trial Of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition And Stereotactic Body Radiotherapy In Prostate Cancer (ASCLEPIuS) - Mayo Clinic

   Uncontrolled diabetes or known HbA1c >10. Any gastrointestinal disorder affecting absorption. Active pituitary or adrenal dysfunction. Patients with ...

7. Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma - Mayo Clinic

   ... HbA1c ≤ 8%, or a fasting serum glucose ≤ 110% ULN; HIV-positive patients must have CD4 count ≥ 400/mm³; No co-morbid systemic illnesses or other severe ...

8. Fenofibrate For Prevention Of DR Worsening - Mayo Clinic

   HbA1c > 11.0% based on central laboratory value or if lab sample cannot be analyzed, recent result within 3 months. Systemic anti-VEGF or pro-VEGF treatment ...

9. A Study of the Safety, Effectiveness and Maximum Tolerated Dose of Oral PQR309 for Patients with Advanced Solid Tumors - Mayo Clinic

   ... HbA1c > 7%; Is currently receiving warfarin for treatment, prophylaxis or otherwise; Has symptomatic congestive heart failure, myocardial infarction ≤ 6 ...

10. A Study To Evaluate The Safety And Effectiveness Of Bimagrumab On Improvement In Total Lean Body Mass And Physical Performance Following Surgical Treatment Of Hip Fracture. - Mayo Clinic

    ... HbA1C ≥ 8% or average blood glucose ≥ 9.0 mmol/l); Significant coagulopathy, platelet count less than 75,000/mm3, or anemia (hemoglobin less than 8.0 g/dL) ...